Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple marker second trimester serum screening for pre-eclampsia.

N J Wald1, J K Morris

  • 1Department of Environmental and Preventive Medicine, Wolfson Institute of Preventive Medicine, St Bartholomew's and the Royal London School of Medicine and Dentistry, UK. n.j.wald@mds.qmw.ac.uk

Journal of Medical Screening
|August 2, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Linking a European cohort of children born with congenital anomalies to vital statistics and mortality records: A EUROlinkCAT study.

PloS one·2021
Same author

Prevalence of Down's Syndrome in England, 1998-2013: Comparison of linked surveillance data and electronic health records.

International journal of population data science·2020
Same author

Correction to: EUROCAT: an update on its functions and activities.

Journal of community genetics·2018
Same author

Estimating the birth prevalence and pregnancy outcomes of congenital malformations worldwide.

Journal of community genetics·2018
Same author

EUROCAT: an update on its functions and activities.

Journal of community genetics·2018
Same author

Pregnancy-associated plasma protein-A truncation limits in antenatal screening for trisomy 18.

Journal of medical screening·2017
Same journal

Cost-benefit analysis of an organized community-based multi-cancer screening program in Bangladesh.

Journal of medical screening·2026
Same journal

Response to: Adjusting for non-compliance and contamination with a more plausible assumption.

Journal of medical screening·2026
Same journal

Response to Takahashi regarding Bestwick and Wald: Mischaracterisation of evidence in prostate cancer screening.

Journal of medical screening·2026
Same journal

No-cost envelope modification improves fecal immunochemical test laboratory acceptance in a US Veterans Affairs colorectal cancer screening trial.

Journal of medical screening·2026
Same journal

Prostate cancer screening: The level of the evidence hierarchy.

Journal of medical screening·2026
Same journal

Prediction model to prioritize colorectal cancer screening with visual colonoscopy.

Journal of medical screening·2026
See all related articles

Maternal serum screening using inhibin A, free beta-human chorionic gonadotropin (free beta-hCG), and unconjugated estriol (uE3) can effectively screen for pre-eclampsia in the second trimester. This combination detects 55% of pre-eclampsia cases with a 5% false positive rate.

Area of Science:

  • Obstetrics and Gynecology
  • Maternal-Fetal Medicine
  • Biochemical Markers in Pregnancy

Background:

  • Pre-eclampsia is a significant complication of pregnancy.
  • Second-trimester screening for pre-eclampsia is crucial for timely intervention.
  • Current screening methods have limitations in accuracy and timing.

Purpose of the Study:

  • To evaluate the efficacy of a combined maternal serum screening test for pre-eclampsia.
  • To assess the utility of inhibin A, free beta-hCG, uE3, and AFP in second-trimester pre-eclampsia detection.
  • To determine the potential of these biomarkers for early identification of at-risk pregnancies.

Main Methods:

  • Serum samples from women with and without pre-eclampsia were analyzed.
  • Levels of inhibin A, free beta-hCG, uE3, and AFP were measured.

Related Experiment Videos

  • Samples were collected in the second trimester, at least two weeks prior to clinical diagnosis.

    • Main Results:

    • Elevated median levels of inhibin A and free beta-hCG were observed in pre-eclamptic pregnancies.
    • Lowered median levels of uE3 were found in pregnancies that developed pre-eclampsia.
    • Alpha-fetoprotein (AFP) levels did not differ significantly between affected and unaffected pregnancies.
    • A combined test using inhibin A, free beta-hCG, and uE3 detected 55% of pre-eclampsia cases with a 5% false positive rate.

    Conclusions:

    • A combination of inhibin A, free beta-hCG, and uE3 shows promise as a second-trimester screening tool for pre-eclampsia.
    • This biomarker panel may aid in the early identification of pregnancies at risk for pre-eclampsia.
    • Further validation may lead to improved prenatal care strategies for pre-eclampsia.